WR 279,396

Phase 2Small molecule

UU.S. Army Medical Research and Development Command

WR 279,396 is one of 34 small molecule programs targeting Leishmaniasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeishmaniasisActive, not recruiting

Cutaneous LeishmaniasisActive, not recruiting

LeishmaniasisPreclinical

Active, not recruiting

Cutaneous LeishmaniasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Cutaneous Leishmaniasis

#DrugCompanyPhaseTrials

Levaquin

WWim Janssens

Approved

—2

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Garamycin

Impavido

KKnight Therapeutics (USA) Inc

Phase 3

12 5

Meglumine Antimoniate

UUniversity of Brasilia

Approved

14 6

Pentam

FFresenius Kabi Oncology Ltd.

Phase 3

2 7

Aldara

BBausch Health Americas, Inc.

Phase 3

1 8

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Cipro

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis8 trials

Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00703924·92 enrolled

Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT00606580·375 enrolled

Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01083576·30 enrolled

Show 5 more trials

Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01032382·30 enrolled

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT01790659·399 enrolled

Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis

Terminated·UU.S. Army Medical Research and Development Command·Phase 2·NCT01140191·1 enrolled

A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT01536795·48 enrolled

WR 279,396 for the Treatment of Cutaneous Leishmaniasis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01988909·18 enrolled

Treatment1 trial

WR 279,396 Open Label Treatment Protocol in Tunisia

Terminated·UU.S. Army Medical Research and Development Command·Phase 2·NCT01494350·50 enrolled

Leishmaniasis1 trial

Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application

Completed·UU.S. Army Medical Research and Development Command·N/A·NCT00490230·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for WR 279,396. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WR 279,396 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WR 279,396. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — U.S. Army Medical Research and Development Command company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UU.S. Army Medical Research and Development Command

WR 279,396

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous Leishmaniasis8 trials

Treatment1 trial

Leishmaniasis1 trial

References

Drug Info

Quick Facts

Related News